Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 1 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Lenvatinib And Stereotactic radiothErapy With pembRolizumab in Metastatic Kidney Cancer PatientsRecruitingNCT07928167Phase 2 Report a problem
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal CancerNot yet recruitingNCT07923877Phase 2 Report a problem
Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast CancerNot yet recruitingNCT07914309Phase 2 Report a problem
A Phase 1 Trial of KAN-001 With Pembrolizumab, With or Without Chemotherapy, in Participants With PD-L1-Positive Non-Small Cell Lung CancerNot yet recruitingNCT07910942Phase 1 Report a problem
A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or in Combination With Other Cancer Therapies in People With Solid Tumors With a Rat Sarcoma Viral Oncogene Homolog Glycine 12 Valine (RAS G12V) MutationNot yet recruitingNCT07905924Phase 1 Report a problem
Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later SettingRecruitingNCT07892833Phase 2 Report a problem
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]RecruitingNCT07890714Phase 1/2 Report a problem
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung CancerNot yet recruitingNCT07890493Phase 2 Report a problem
Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07889232Phase 1/2 Report a problem
Optimizing Response to Immunotherapy With Online Adaptive Pulsed Radiotherapy in Incurable Head and Neck CancersNot yet recruitingNCT07888816Phase 2 Report a problem
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingNCT07886905Phase 2 Report a problem
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2 Report a problem
Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast CancerNot yet recruitingNCT07884721Not applicable Report a problem
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingNCT07877584Phase 3 Report a problem
Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingNCT07870772Phase 2 Report a problem
US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyNot yet recruitingNCT07862751Phase 2 Report a problem
Labyrinthin Vaccination in Veterans With Lung AdenocarcinomaNot yet recruitingNCT07859592Phase 2 Report a problem
Histotripsy in Biliary Tract CancerRecruitingNCT07853690Not applicable Report a problem
A Prospective Study of Sacituzumab Tirumotecan Plus Pembrolizumab for Advanced Biliary Tract CancerRecruitingNCT07850791Phase 2 Report a problem
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07845786Phase 2 Report a problem
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingNCT07840456Phase 2 Report a problem
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingNCT07829783Phase 3 Report a problem
Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk WallNot yet recruitingNCT07823491Phase 3 Report a problem
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or RectumRecruitingNCT07811193Phase 2 Report a problem
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon CancerRecruitingNCT07808151Phase 2 Report a problem
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or MetastaticRecruitingNCT07807345Phase 1 Report a problem
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCRecruitingNCT07807163Phase 2 Report a problem
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung CancerRecruitingNCT07802821Phase 3 Report a problem
Molecularly Tailored Therapy in Advanced Pancreatic CancerNot yet recruitingNCT07802418Phase 2 Report a problem
A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory LymphomaNot yet recruitingNCT07791615Phase 2 Report a problem
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI TrialRecruitingNCT07783581Phase 2 Report a problem
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCRecruitingNCT07777822Phase 3 Report a problem
Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck CancerRecruitingNCT07773987Phase 2 Report a problem
Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal CancerNot yet recruitingNCT07772882Phase 1 Report a problem
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingNCT07770100Phase 2 Report a problem
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingNCT07762716Phase 1/2 Report a problem
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingNCT07762703Phase 1/2 Report a problem
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabRecruitingNCT07751042Phase 1/2 Report a problem
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3 Report a problem
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsRecruitingNCT07749586Phase 1/2 Report a problem
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT07744126Phase 2 Report a problem
A Study of DS-3939a in Participants With Solid TumorsRecruitingNCT07739966Phase 1/2 Report a problem
RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerNot yet recruitingNCT07732634Phase 2 Report a problem
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruitingNCT07730021Phase 1/2 Report a problem
Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and PembrolizumabNot yet recruitingNCT07720180Phase 2 Report a problem
Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell CancerRecruitingNCT07718854Phase 2 Report a problem
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBCRecruitingNCT07698106Phase 1/2 Report a problem
EWSR1 Immunotherapy in Ewing Sarcoma and DSRCTNot yet recruitingNCT07695311Phase 1 Report a problem
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat SyndromeNot yet recruitingNCT07691645Phase 2 Report a problem
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07691476Phase 2 Report a problem
Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal CancerRecruitingNCT07687875Phase 1 Report a problem
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone MetastasesNot yet recruitingNCT07687225Not applicable Report a problem
Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell CarcinomaNot yet recruitingNCT07686744Phase 1 Report a problem
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)RecruitingNCT07684599Phase 3 Report a problem
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingNCT07673887Phase 3 Report a problem
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC ParticipantsRecruitingNCT07668154Phase 2 Report a problem
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial CancerRecruitingNCT07667335Phase 1/2 Report a problem
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerNot yet recruitingNCT07662720Phase 1/2 Report a problem
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)RecruitingNCT07660094Phase 3 Report a problem
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast CancerRecruitingNCT07652242Phase 1 Report a problem
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced MalignanciesRecruitingNCT07644039Phase 1/2 Report a problem
N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid TumorsRecruitingNCT07639450Phase 1/2 Report a problem
Sitagliptin With Pembro in RCC and MelanomaRecruitingNCT07634380Phase 1 Report a problem
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian CancerNot yet recruitingNCT07634094Phase 2 Report a problem
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.Not yet recruitingNCT07633613Phase 4 Report a problem
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic CholangiocarcinomaNot yet recruitingNCT07632235Phase 1/2 Report a problem
Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)Not yet recruitingNCT07629700Not applicable Report a problem
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07622186Phase 2 Report a problem
A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving PembrolizumabRecruitingNCT07619599Phase 1 Report a problem
Intermittent Hypoxic Training as Neoadjuvant Therapy for Lung Squamous Cell CarcinomaNot yet recruitingNCT07618793Phase 2 Report a problem
Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid MalignanciesRecruitingNCT07610941Phase 1 Report a problem
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER TrialNot yet recruitingNCT07610525Phase 2 Report a problem
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaRecruitingNCT07601737Phase 2 Report a problem
Universal Immunization to Fortify Immunotherapy Efficacy and ResponseRecruitingNCT07597070Phase 2 Report a problem
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell CarcinomaNot yet recruitingNCT07593040Phase 2 Report a problem
A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal CancerNot yet recruitingNCT07591597Phase 1/2 Report a problem
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE TrialRecruitingNCT07579195Phase 1/2 Report a problem
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III MelanomaRecruitingNCT07565285Phase 2 Report a problem
Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruitingNCT07552558Phase 1/2 Report a problem
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast CancerNot yet recruitingNCT07552181Phase 2 Report a problem
Acupuncture and Exercise for EV-Pembro-Induced Peripheral NeuropathyRecruitingNCT07548476Not applicable Report a problem
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)RecruitingNCT07513376Phase 3 Report a problem
Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCCRecruitingNCT07509099Phase 3 Report a problem
Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck CancerRecruitingNCT07501650Phase 1 Report a problem
Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-lineRecruitingNCT07501351Phase 2 Report a problem
Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)RecruitingNCT07485296Phase 2 Report a problem
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Not yet recruitingNCT07484139Phase 2 Report a problem
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerRecruitingNCT07484022Phase 1 Report a problem
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07469774Phase 1/2 Report a problem
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver MetastasesNot yet recruitingNCT07466927Phase 2 Report a problem
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCRecruitingNCT07465276Phase 2 Report a problem
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationRecruitingNCT07458347Phase 1 Report a problem
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell CarcinomasRecruitingNCT07455032Phase 1 Report a problem
QLS5132 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07453394Phase 1/2 Report a problem
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung CancerRecruitingNCT07452224Phase 2 Report a problem
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)RecruitingNCT07431827Phase 3 Report a problem
Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT07428148Phase 1/2 Report a problem
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingNCT07415031Phase 2 Report a problem
Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCCNot yet recruitingNCT07412054Phase 2 Report a problem
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid TumorsRecruitingNCT07410676Phase 1/2 Report a problem

← Pembrolizumab